Rémy Duléry
@remydulery.bsky.social
MD, PhD in Hematology Oncology.
HSC transplantation • Cellular therapy • CAR T-cell • CAR NK cell • Lymphoma management • Cardio-oncology • QoL.
Researcher at Dana-Farber Cancer Institute, Harvard Medical School (#RomeeLab).
HSC transplantation • Cellular therapy • CAR T-cell • CAR NK cell • Lymphoma management • Cardio-oncology • QoL.
Researcher at Dana-Farber Cancer Institute, Harvard Medical School (#RomeeLab).
✅ Takeaway: For optimal protection, vaccination should be completed BEFORE starting lymphoma treatment with B-cell depleting agent, followed by a booster AFTERWARD.
#CovidVaccine #Lymsm
www.frontiersin.org/journals/imm...
#CovidVaccine #Lymsm
www.frontiersin.org/journals/imm...
Frontiers | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine
www.frontiersin.org
February 9, 2025 at 4:54 PM
✅ Takeaway: For optimal protection, vaccination should be completed BEFORE starting lymphoma treatment with B-cell depleting agent, followed by a booster AFTERWARD.
#CovidVaccine #Lymsm
www.frontiersin.org/journals/imm...
#CovidVaccine #Lymsm
www.frontiersin.org/journals/imm...
🔹 Key findings: During lymphoma treatment, CD4, CD8, and B-cell counts dropped. While T-cell responses to SARS-CoV-2 remained intact, antibody production was significantly reduced when vaccinated during therapy. In contrast, patients vaccinated before treatment had a much stronger antibody response.
February 9, 2025 at 4:54 PM
🔹 Key findings: During lymphoma treatment, CD4, CD8, and B-cell counts dropped. While T-cell responses to SARS-CoV-2 remained intact, antibody production was significantly reduced when vaccinated during therapy. In contrast, patients vaccinated before treatment had a much stronger antibody response.
That’s why we launched the Lymphocovac study—a prospective, case-control, multicenter trial (NCT05050461) to understand how these treatments impact T-cell and antibody responses to COVID-19 mRNA vaccines.
www.frontiersin.org/journals/imm...
www.frontiersin.org/journals/imm...
Frontiers | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine
www.frontiersin.org
February 9, 2025 at 4:54 PM
That’s why we launched the Lymphocovac study—a prospective, case-control, multicenter trial (NCT05050461) to understand how these treatments impact T-cell and antibody responses to COVID-19 mRNA vaccines.
www.frontiersin.org/journals/imm...
www.frontiersin.org/journals/imm...
But vaccination remains a challenge for these patients. Anti-CD20 therapies suppress the immune system, making it harder to mount an effective response.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies wi…
www.sciencedirect.com
February 9, 2025 at 4:54 PM
But vaccination remains a challenge for these patients. Anti-CD20 therapies suppress the immune system, making it harder to mount an effective response.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Patients with B-cell lymphoma were initially at high risk of severe and prolonged #COVID19, especially those on B-cell-depleting treatments. Thankfully, with the rise of Omicron, antiviral therapies, and widespread vaccination, COVID-19 mortality dropped to 6%
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy
Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma an...
onlinelibrary.wiley.com
February 9, 2025 at 4:54 PM
Patients with B-cell lymphoma were initially at high risk of severe and prolonged #COVID19, especially those on B-cell-depleting treatments. Thankfully, with the rise of Omicron, antiviral therapies, and widespread vaccination, COVID-19 mortality dropped to 6%
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
I am very happy this prospective study is finally out! Congratulations for the excellent work on the manuscript. Et à bientôt j’espère !
February 8, 2025 at 11:56 PM
I am very happy this prospective study is finally out! Congratulations for the excellent work on the manuscript. Et à bientôt j’espère !
Thanks. I am also one of the co-authors and I am excited to finally see this great collaborative study published in your journal. 😊
January 26, 2025 at 7:12 PM
Thanks. I am also one of the co-authors and I am excited to finally see this great collaborative study published in your journal. 😊